1stOncology™: Cancer Intelligence Service – Page 2 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024

On April 25, 2024 Compugen Ltd. (NASDAQ: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present new clinical data on COM701 (anti-PVRIG) in triple combination with COM902 (anti-TIGIT) and pembrolizumab in microsatellite stable colorectal cancer at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting on May31-June 4 2023, in Chicago, Illinois (Press release, Compugen, APR 25, 2024, View Source [SID1234642366]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Poster Presentation Details:

Title: Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases

Abstract Number: 3597

Session Title: Gastrointestinal Cancer – Colorectal and Anal

Lead Author: Dr. Manish Sharma

Date: Saturday, June 1, 2024; 1:30PM-4:30PM CDT

Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

On April 25, 2024 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, reported the presentation of four abstracts (including one oral presentation and three poster presentations) at the 2024 American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place from May 31st to June 4th at the McCormick Place Convention Center in Chicago, IL, the United States (Press release, Antengene, APR 25, 2024, View Source [SID1234642365]).

Details of the Oral Presentation:

ATG-008 (mTORC1/2 Inhibitor)
Title: A phase I/II study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort
Abstract: 5509
Session: Clinical Science Symposium – Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum
Date: June 1, 2024
Time: 1:15 PM – 2:45 PM (Central Daylight Time)
2:15 AM – 3:45 AM, June 2, 2024 (Beijing Time)

Details of the Poster Presentations:

ATG-031 (anti-CD24 monoclonal antibody)
Title: A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM)
Abstract: TPS2691
Session: Developmental Therapeutics—Immunotherapy
Date: June 1, 2024
Time: 9:00 AM – 12:00 PM (Central Daylight Time)
10:00 PM, June 1 – 1:00 AM, June 2, 2024 (Beijing Time)

ATG-022 (Claudin 18.2 Antibody-drug Conjugate)
Title: An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH)
Abstract: 3032
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date: June 1, 2024
Time: 9:00 AM – 12:00 PM (Central Daylight Time)
10:00 PM, June 1 – 1:00 AM, June 2, 2024 (Beijing Time)

Selinexor (XPO1 Inhibitor)
Title: Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH)
Abstract: 7065
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Date: June 3, 2024
Time: 9:00 AM – 12:00 PM (Central Daylight Time)
10:00 PM, June 3 – 1:00 AM, June 4, 2024 (Beijing Time)

AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

On April 25, 2024 AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, reported the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in Chicago May 31 to June 4, 2024 (Press release, AbelZeta, APR 25, 2024, View Source [SID1234642364]). C-CAR031 is based on a novel GPC3-targeting CAR-T designed by AstraZeneca (LSE/STO/Nasdaq: AZN) using their transforming growth factor-beta receptor II (TGFβRII) dominant negative armoring discovery platform and is manufactured by AbelZeta in China. C-CAR031 is being developed in China under a co-development agreement between AbelZeta and AstraZeneca.1

Details of the oral presentation are as follows:

Abstract Title: "Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)."
Abstract Number: 4019
Session Type and Title: Rapid Oral Abstract – Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Session Date and Time: 6/3/2024; 9:45 AM-11:15 AM CDT

Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor

On April 25, 2024 Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, reported that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented in an oral presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, which will be held in Chicago, USA, from May 31-June 4, 2024 (Press release, Mabwell Biotech, APR 25, 2024, View Source;mabwell-to-present-clinical-data-of-9mw2821-in-multiple-advanced-solid-tumor-302127436.html [SID1234642363]).

Oral Presentation

Abstract Title: 9MW2821, a nectin-4 antibody-drug conjugate (ADC), in patients with advanced solid tumor: Results from a phase 1/2a study.
Session Date and Time: 6/3/2024; 8:00 AM-9:30 AM CDT
Presenter: Prof. Zhang Jian Chief Physician/Doctoral Supervisor (Fudan University Shanghai Cancer Center)
Abstract Number for Publication: 3013

About 9MW2821

9MW2821 is the first site-specific conjugated novel ADC targeting Nectin-4 developed by Mabwell using ADC platform and automated high-throughput hybridoma antibody molecular discovery platform, and is the first drug candidate to enter clinical study among the Nectin-4-targeting ADCs developed by Chinese companies. Multiple clinical studies of 9MW2821 have been conducted in China to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of 9MW2821 in patients with various advanced solid tumors.

The phase III clinical study of 9MW2821 monotherapy has officially been initiated in patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-based chemotherapy and PD-(L)1 inhibitor therapy. The phase I/II clinical study of 9MW2821 in combination with PD-1 inhibitors is also ongoing, with the first patient already enrolled. 9MW2821 was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) in February 2024 for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma. Currently, 9MW2821 is the first therapeutic drug candidate targeting Nectin-4 in the world to disclose clinical efficacy and safety data for indications of cervical cancer and esophageal carcinoma.

Theriva™ Biologics to Discuss the Trial Design for VIRAGE – a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma – at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

On April 25, 2024 Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, reported that, based on the strength of the science and its relevance, VIRAGE – the Phase 2b randomized, open-label, placebo-controlled, multicenter clinical trial of systemically administered VCN-01 in combination with standard-of-care (SoC) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC) – has been accepted for presentation as a trial-in-progress poster at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, being held in Chicago, IL, from May 31-June 4 (Press release, Theriva Biologics, APR 25, 2024, View Source [SID1234642361]).

ASCO Presentation Details

Title: VIRAGE: A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer
Presenter: Dr. Rocío García-Carbonero
Session Title: Poster Session – Gastrointestinal Cancer: Gastroesophageal, Pancreatic, and Hepatobiliary
Poster Session Date and Time: 01 June 2024, 1:30 PM-4:30 PM US CDT
Abstract Number: TPS4210